| scholarly article | Q13442814 |
| P50 | author | Aaron T Gerds | Q49680028 |
| Hans Joachim Deeg | Q75039559 | ||
| P2860 | cites work | Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients | Q46052631 |
| Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. | Q50558385 | ||
| WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) | Q81322446 | ||
| Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia | Q82236404 | ||
| Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome | Q82366072 | ||
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 | ||
| Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study | Q33391089 | ||
| Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia | Q33706393 | ||
| Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia | Q33861150 | ||
| In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. | Q33997187 | ||
| A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome | Q34308142 | ||
| Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome | Q34924442 | ||
| Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities | Q35000581 | ||
| Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. | Q35835657 | ||
| Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol | Q35925067 | ||
| Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders | Q36484688 | ||
| Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure | Q36877036 | ||
| Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review | Q37937818 | ||
| Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia | Q40630235 | ||
| Report of an international working group to standardize response criteria for myelodysplastic syndromes. | Q40737646 | ||
| Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. | Q43757318 | ||
| Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors | Q44099372 | ||
| 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. | Q45960014 | ||
| P433 | issue | 2 | |
| P921 | main subject | myelodysplastic syndrome | Q954625 |
| P304 | page(s) | 71-75 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Current Opinion in Hematology | Q15757961 |
| P1476 | title | Transplantation for myelodysplastic syndrome in the era of hypomethylating agents | |
| P478 | volume | 19 |
| Q36703031 | A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia |
| Q39023384 | Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia |
| Q30252975 | Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes |
| Q38132814 | When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents? |
| Q38148983 | When to transplant MDS, and what to do when transplant fails |
Search more.